You will be shown the abstract of a medical clinical trial report. Your task is to extract all the findings from this report into a JSON array. Each finding should contain the following five elements:

- Intervention: The medical intervention being tested. This should be a text span copied from the input passage.
- Comparator: The baseline against which the intervention is being evaluated. This should be a text span copied from the input passage. If no comparator is reported, set to `null`.
- Outcome: The medical outcome whose effect is being measured. This should be a text span copied from the input passage.
- Effect: The effect of the intervention on the outcome, relative to the comparator. The effect should be one of the following three values: ("significantly increased", "significantly decreased", "no significant difference").
- Evidence: The evidence for the effect. This should be a text span copied from the input passage.

Please format your output as a JSON array. Each entry in the output should be an array containing the 5 elements listed above, in the following order: [<intervention>, <comparator>, <outcome>, <effect>, <evidence>].

For example, an output with two findings might read:
```
[["aspirin", "placebo", "headache severity", "significantly decreased", "Mean headache severity was significantly decreased in the aspirin group compared to the placebo group (p < 0.05)."], ["aspirin", "placebo", "weight loss", "no significant difference", "We did not observe any difference in weight loss between the group given aspirin relative to the control group"]]
```

There are 7 finding(s) in the abstract below. Please extract them. Output only the JSON array with these 7 findings. Do not include any additional text.

Abstract:
ABSTRACT.BACKGROUND: The efficacy and safety of olanzapine monotherapy are evaluated in Japanese patients from a large, global study of bipolar depression.

ABSTRACT.METHODS: This is an analysis of Japanese patients from a 6-week, global (Japan, China, Korea, Taiwan, and the United States), randomized, double-blind, placebo-controlled, Phase 3 study of patients with a depressive episode of bipolar I disorder. The primary outcome was baseline-to-endpoint change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Secondary outcome measures included the Clinical Global Impressions-Bipolar Version Severity of Illness Scale (CGI-BP), the 17-item Hamilton Depression Rating Scale (HAMD-17) total score, the Young Mania Rating Scale (YMRS) total score, and rates of response (≥50% baseline-to-endpoint reduction in MADRS total score), recovery, and remission.

ABSTRACT.RESULTS: Of the 156 Japanese patients, 104 had been allocated to olanzapine and 52 to placebo. All results are baseline-to-endpoint change. Compared to placebo, patients in the olanzapine group experienced greater improvement in the primary outcome measure, MADRS total score (−14.9 vs. −10.7; p = .01). They also had greater reductions in the following secondary measures: CGI- BP Depression (−1.41 vs. -0.89; p = .008), CGI-BP Bipolar (−1.31 vs. −0.83; p = .01), HAMD-17 (−11.7 vs. −7.9; p < .01), and YMRS (-0.32 vs. 0.34; p = .03). Differences in rates of response, recovery, and remission were not statistically significant. A greater proportion of olanzapine-treated patients reported treatment- emergent adverse events (87.5% vs. 59.6%; p < .001). Patients treated with olanzapine had greater increases in weight (p < .001) and fasting total cholesterol (p = .008); fasting triglycerides (p = .02), and fasting low-density lipoprotein (p = .01). There was a greater reduction in fasting high-density lipoprotein in olanzapine-treated patients (p = .01). Compared with placebo-group patients, more olanzapine-group patients shifted from borderline to high cholesterol (25.0% vs. 0.0%; p = .007) and had clinically significant weight gain (≥7% body weight) (20.2% vs. 1.9%; p = .001).

ABSTRACT.CONCLUSIONS: Results of this analysis support the efficacy and tolerability of olanzapine for the treatment of bipolar depression in Japanese patients. Results in this population were consistent with those seen in the more ethnically diverse parent study. In making treatment decisions for individual patients, clinicians should carefully consider the risks and benefits of olanzapine treatment.

ABSTRACT.TRIAL REGISTRATION: Clinicatrials.gov ID NCT00510146 Olanzapine Treatment of Patients with Bipolar I Disorder

Findings:
[["olanzapine", "placebo", "improvement in the primary outcome measure, MADRS total score", "significantly increased", "Compared to placebo, patients in the olanzapine group experienced greater improvement in the primary outcome measure, MADRS total score (\u221214.9 vs. \u221210.7; p\u2009=\u2009.01)."], ["olanzapine", "placebo", "reductions in the following secondary measures: CGI- BP Depression", "significantly increased", "They also had greater reductions in the following secondary measures: CGI- BP Depression (\u22121.41 vs. -0.89; p\u2009=\u2009.008),"], ["olanzapine", "placebo", "rates of response, recovery, and remission", "no significant difference", "Differences in rates of response, recovery, and remission were not statistically significant."], ["olanzapine", "placebo", "treatment- emergent adverse events", "significantly increased", "A greater proportion of olanzapine-treated patients reported treatment- emergent adverse events (87.5% vs. 59.6%; p\u2009\u0026lt;\u2009.001)."], ["olanzapine", "placebo", "treatment- emergent adverse events", "significantly increased", "A greater proportion of olanzapine-treated patients reported treatment- emergent adverse events (87.5% vs. 59.6%; p\u2009\u003c\u2009.001). Patients treated with olanzapine had greater increases in weight (p\u2009\u003c\u2009.001) and fasting total cholesterol (p\u2009=\u2009.008); fasting triglycerides (p\u2009=\u2009.02), and fasting low-density lipoprotein (p\u2009=\u2009.01)."], ["olanzapine", "placebo", " number of patients shifted from borderline to high cholesterol", "significantly increased", "Compared with placebo-group patients, more olanzapine-group patients shifted from borderline to high cholesterol (25.0% vs. 0.0%; p\u2009=\u2009.007)"], ["olanzapine", "placebo", "weight gain", "significantly increased", "Compared with placebo-group patients, more olanzapine-group patients shifted from borderline to high cholesterol (25.0% vs. 0.0%; p\u2009=\u2009.007) and had clinically significant weight gain (\u22657% body weight) (20.2% vs. 1.9%; p\u2009=\u2009.001)."]]